ONEA Stock Overview
Engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Oneness Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$22.00 |
| 52 Week High | NT$0 |
| 52 Week Low | NT$0 |
| Beta | 1.59 |
| 11 Month Change | -11.29% |
| 3 Month Change | -10.57% |
| 1 Year Change | -18.52% |
| 33 Year Change | -35.67% |
| 5 Year Change | n/a |
| Change since IPO | -56.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| ONEA | LU Pharmaceuticals | LU Market | |
|---|---|---|---|
| 7D | -4.3% | 0% | 0% |
| 1Y | -18.5% | 0% | 0% |
Return vs Industry: ONEA underperformed the Luxembourg Pharmaceuticals industry which returned 13% over the past year.
Return vs Market: ONEA underperformed the Luxembourg Market which returned 4.4% over the past year.
Price Volatility
| ONEA volatility | |
|---|---|
| ONEA Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in LU Market | 0% |
| 10% least volatile stocks in LU Market | 0% |
Stable Share Price: ONEA's share price has been volatile over the past 3 months.
Volatility Over Time: ONEA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Luxembourg stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Shuling Cheng | www.onenessbio.com |
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials.
Oneness Biotech Co., Ltd. Fundamentals Summary
| ONEA fundamental statistics | |
|---|---|
| Market cap | US$2.10b |
| Earnings (TTM) | -US$30.72m |
| Revenue (TTM) | US$3.20m |
655.4x
P/S Ratio-68.2x
P/E RatioIs ONEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ONEA income statement (TTM) | |
|---|---|
| Revenue | NT$101.93m |
| Cost of Revenue | NT$52.77m |
| Gross Profit | NT$49.15m |
| Other Expenses | NT$1.03b |
| Earnings | -NT$978.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.05 |
| Gross Margin | 48.22% |
| Net Profit Margin | -960.39% |
| Debt/Equity Ratio | 0% |
How did ONEA perform over the long term?
See historical performance and comparison